-
Product Insights
NewNet Present Value Model: Autolus Therapeutics Plc’s AUTO-8
Empower your strategies with our Net Present Value Model: Autolus Therapeutics Plc's AUTO-8 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Applied Therapeutics Inc’s Gavorestat
Empower your strategies with our Net Present Value Model: Applied Therapeutics Inc's Gavorestat report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AUTO-8 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AUTO-8 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AUTO-8 in Relapsed Multiple Myeloma Drug Details: AUTO-8 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AUTO-8 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AUTO-8 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AUTO-8 in Refractory Multiple Myeloma Drug Details: AUTO-8 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Spartalizumab in Anal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Spartalizumab in Anal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Spartalizumab in Anal Cancer Drug Details: Spartalizumab (PDR-001) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Spartalizumab in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Spartalizumab in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Spartalizumab in Pancreatic Ductal Adenocarcinoma Drug Details: Spartalizumab (PDR-001) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pidnarulex in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pidnarulex in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pidnarulex in Prostate Cancer Drug Details: Pidnarulex is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TT-11X in Natural Killer Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TT-11X in Natural Killer Cell Lymphomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TT-11X in Natural Killer Cell Lymphomas Drug Details: TT-11X is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Merkel Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Merkel Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Merkel Cell Carcinoma Drug Details: RP-1 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Niraparib in Oligodendroglioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Niraparib in Oligodendroglioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Niraparib in Oligodendroglioma Drug Details: Niraparib (MK-4827, Zejula) is an anti-neoplastic agent....